Peptide profiling in epithelial tumor plasma by the emerging proteomic techniques

Area of Science:

• Proteomics
• Biomarker Discovery
• Cancer Research

Background:

• Plasma peptide components (PPC) are increasingly studied for their potential as cancer biomarkers.
• Distinguishing between different cancer types and healthy individuals based on plasma proteomic profiles is a significant challenge.

Purpose of the Study:

• To investigate and differentiate plasma peptide profiles in melanoma and breast cancer patients compared to healthy controls.
• To identify specific peptide markers associated with melanoma and breast cancer.

Main Methods:

• Utilized a combination of Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC), Surface-Enhanced Laser Desorption/Ionization Time-of-Flight Mass Spectrometry (SELDI-TOF MS), and tandem mass spectrometry.
• Analyzed plasma peptide components from ten individuals in each group: melanoma, breast cancer, and healthy controls.

Main Results:

• A distinct three-peak pattern (2023, 2039, 2053.5 m/z) was predominantly observed in melanoma samples.
• Two unique peaks (2236.1 and 2356.3 m/z) were exclusively detected in breast cancer samples.
• Specific fragments of fibrinogen alpha and inter-alpha-trypsin inhibitor heavy chain H4 were found to be absent in both melanoma and breast cancer samples.

Conclusions:

• Plasma peptide profiling can differentiate between melanoma, breast cancer, and healthy individuals.
• Specific peptide mass-to-charge ratios (m/z) show potential as diagnostic markers for melanoma and breast cancer.
• The absence of certain protein fragments may also serve as a distinguishing feature in cancer diagnostics.